Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. | Leukemia;31(5): 1253-1254, 2017 05. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring, A M; Page, B D G; Kraft, I L; Mason, C C; Vellore, N A; Resetca, D; Zabriskie, M S; Zhang, T Y; Khorashad, J S; Engar, A J; Reynolds, K R; Anderson, D J; Senina, A; Pomicter, A D; Arpin, C C; Ahmad, S; Heaton, W L; Tantravahi, S K; Todic, A; Colaguori, R; Moriggl, R; Wilson, D J; Baron, R; O'Hare, T; Gunning, P T; Deininger, M W.

Leukemia ; 31(5): 1253-1254, 2017 05.

Article in En | MEDLINE | ID: mdl-28465516

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2017 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2017 Document type: Article Country of publication: